Lenvatinib: Phase Ib/II data

Data from 78 evaluable patients with stage IV melanoma in the modified intent-to-treat (mITT) population of the Phase II portion of a Phase Ib/II trial showed that 20 mg oral lenvatinib

Read the full 319 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE